Glaucoma drug compliance linked to age

Article

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease.

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease, according to a report presented at the annual meeting of the French Society of Ophthalmology.

Florent Aptel, MD and colleagues asked patients to complete a questionnaire concerning non-observance of treatment schedules. In addition, visual field examinations were performed and patients were asked to apply eye drops in the same way as they would at home.

Twenty-four percent of patients admitted non-compliance and approximately 20% instilled their drops outside of the eye. The non-compliant patients were mainly younger or those with earlier stages of the disease. Those who had difficulty in applying the drops tended to be older, with poorer visual acuity and larger visual field defects.

Based on this data the researchers identified two typical patient groups. The first are the relatively young patients with early stage glaucoma, which does not have a significant impact on their life. These subjects are able to carry out the instillation properly but are likely to be less compliant. The second group comprises of the older patients who have more advanced glaucoma, which does have a significant impact on their day-to-day life. These are more compliant but have difficulties performing the instillation correctly, often allowing all or part of the medication to drop outside of the eye.

This study suggests that compliance and drug administration in glaucoma patients can be directly correlated to age and disease severity.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.